Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer

doi:10.3748/wjg.v31.i24.108298

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 24

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (34)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-7) series, Tables (1-7) series.

Item

Count

PDF

HTML

Figures (1-7)

Tables (1-7)

Sum=33

Jun 28, 2025 (publication date) through Jun 26, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Jun 28, 2025; 31(24): 108298
Published online Jun 28, 2025. doi: 10.3748/wjg.v31.i24.108298

Table 1 Baseline characteristics and treatment details of patients in the matched cohort, n (%)

Characteristics	Levels	Control group (n = 78)	Experiment group (n = 25)	P value
Age	> 60	33 (42.3)	10 (40)	1.000
Age	≤ 60	45 (57.7)	15 (60)	-
Gender	Male	48 (61.5)	15 (60)	1.000
Gender	Female	30 (38.5)	10 (40)	-
ECOG	1	75 (96.2)	23 (92)	0.759
ECOG	2	3 (3.8)	2 (8)	-
Primary tumor location	Right colon	27 (34.6)	12 (48)	0.335
Primary tumor location	Left colon and rectum	51 (65.4)	13 (52)	-
Primary tumor surgery	No	12 (15.4)	3 (12)	1.000
Primary tumor surgery	Yes	66 (84.6)	22 (88)	-
Number of metastatic organs	1	55 (70.5)	19 (76)	0.783
Number of metastatic organs	≥ 2	23 (29.5)	6 (24)	-
Liver metastasis	No	37 (47.4)	9 (36)	0.441
Liver metastasis	Yes	41 (52.6)	16 (64)	-
Lung metastasis	No	58 (75.3)	19 (76)	1.000
Lung metastasis	Yes	19 (24.7)	6 (24)	-
RAS	Unknown	16 (20.5)	8 (32)	0.496
	Wild-type	15 (19.2)	4 (16)	-
	Mutation	47 (60.3)	13 (52)	-

The control group received chemotherapy combined with bevacizumab. The experimental group received chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy. ECOG: Eastern Cooperative Oncology Group.

Table 2 Comparison of short-term efficacy between two groups of microsatellite stable metastatic colorectal cancer

Group	Number	PR	SD	PD	ORR (%)	DCR (%)
Control group	78	18	53	7	23.08	91.03
Experimental group	25	9	15	1	36.00	96.00
χ² value	-	1.0348	0.2377	-	1.0348	-
P value	-	0.309	0.6258	0.6759¹	0.309	0.6759¹

¹Fisher’s exact test.

Table 3 Univariate and multivariate Cox analysis of the effect of prognostic factors in the original cohort, n (%)

Dependent: Survival (OS/30, status OS)		All patients	HR (univariable)	HR (multivariable)
Gender	Male	87 (64.0)	-	-
Gender	Female	49 (36.0)	0.83 (0.45-1.50, P = 0.531)	1.02 (0.56-1.91, P = 0.928)
Age	> 60	60 (44.1)	-	-
Age	≤ 60	76 (55.9)	1.20 (0.67-2.14, P = 0.540)	1.00 (0.56-1.80, P = 0.995)
ECOG	1	125 (91.9)	-	-
ECOG	2	11 (8.1)	1.14 (0.41-3.19, P = 0.803)	-
Number of metastatic organs	1	80 (58.8)	-	-
Number of metastatic organs	≥ 2	56 (41.2)	1.50 (0.85-2.64, P = 0.163)	-
Primary tumor location	Right colon	51 (37.5)	-	-
Primary tumor location	Left colon and rectum	85 (62.5)	1.15 (0.64-2.07, P = 0.631)	-
Liver metastasis	No	53 (39.0)	-	-
Liver metastasis	Yes	83 (61.0)	3.34 (1.73-6.46, P < 0.001)	3.36 (1.71-6.60, P < 0.001)
Lung metastasis	No	94 (69.1)	-	-
Lung metastasis	Yes	42 (30.9)	0.65 (0.34-1.24, P = 0.192)	-
RAS	Unknown	26 (19.1)	-	-
	Wild type	24 (17.6)	1.00 (0.41-2.43, P = 0.993)	-
	Mutation	86 (63.2)	0.89 (0.42-1.90, P = 0.767)	-
Group	Control group	108 (79.4)	-	-
Group	Experimental group	28 (20.6)	0.80 (0.34-1.89, P = 0.607)	0.80 (0.34-1.91, P = 0.620)

OS: Overall survival; HR: Hazard ratio; ECOG: Eastern Cooperative Oncology Group.

Table 4 Treatment-emergent adverse events in the 103 patients of the matched dataset, n (%)

Toxicities	Experimental group (n = 25)			Control group (n = 78)			P value for grade 1-2	P value for grade 3-4
Toxicities	Grade 0	Grade 1-2	Grade 3-4	Grade 0	Grade 1-2	Grade 3-4	P value for grade 1-2	P value for grade 3-4
Anemia	13 (50.0)	12 (50.0)	0 (0)	53 (70.6)	24 (28.2)	1 (1.2)	0.1831^a	1^b
Neutropenia	18 (69.2)	6 (26.9)	1 (3.8)	40 (51.8)	30 (38.8)	8 (9.4)	0.2807^a	0.4488^b
Leukocytopenia	19 (73.1)	5 (23.1)	1 (3.8)	47 (60.0)	28 (36.5)	3 (3.5)	0.2164^a	1^b
Thrombocytopenia	18 (69.2)	7 (30.8)	0 (0)	44 (55.3)	30 (40.0)	4 (4.7)	0.4782^a	0.5698^b
Proteinuria	23 (92.3)	2 (7.7)	0 (0)	64 (81.2)	14 (18.8)	0 (0)	0.3454^b	1^b
Aspartate transaminase increased	12 (46.2)	13 (53.8)	0 (0)	46 (57.6)	30 (40.0)	2 (2.4)	0.3363^a	1^b
Alanine transaminase increased	14 (53.8)	11 (46.2)	0 (0)	50 (63.5)	26 (35.3)	1 (1.2)	0.4667^a	1^b
Alkaline phosphatase increased	18 (69.2)	7 (30.8)	0 (0)	62 (77.6)	16 (22.4)	0 (0)	0.6126^a	1^b
Blood bilirubin increased	22 (84.6)	3 (15.4)	0 (0)	57 (64.7)	20 (34.1)	1 (1.2)	0.07312^b	1^b
Triglycerides increased	13 (50.0)	10 (42.3)	2 (7.7)	53 (67.1)	22 (29.4)	3 (3.5)	0.3894^a	0.5926^b
Hypothyroidism	23 (92.3)	2 (7.7)	0 (0)	78 (100)	0 (0)	0 (0)	0.0571^b	1^b
Nausea	11 (42.3)	14 (57.7)	0 (0)	31 (41.2)	46 (57.6)	1 (1.2)	0.9765^a	1^b
Vomiting	11 (42.3)	14 (57.7)	0 (0)	47 (58.8)	30 (40.0)	1 (1.2)	0.1901^a	1^b
Fatigue	23 (92.3)	2 (7.7)	0 (0)	58 (72.9)	20 (27.1)	0 (0)	0.09078^b	1^b
Fever	24 (96.2)	1 (3.8)	0 (0)	77 (98.8)	1 (1.2)	0 (0)	0.4283^b	1^b
Rash	23 (92.3)	2 (7.7)	0 (0)	78 (100)	0 (0)	0 (0)	0.05711^b	1^b
Diarrhea	24 (96.2)	1 (3.8)	0 (0)	72 (92.9)	4 (4.7)	2 (2.4)	1^b	1^b
Peripheral neurotoxicity	24 (96.2)	1 (3.8)	0 (0)	75 (96.5)	2 (2.4)	1 (1.2)	0.5698^b	1^b
Hand-foot syndrome	23 (92.3)	1 (3.8)	1 (3.8)	72 (92.9)	5 (5.9)	1 (1.2)	1^b	0.4283^b
Hypertension	24 (96.2)	1 (3.8)	0 (0)	77 (98.8)	0 (0)	1 (1.2)	0.2427^b	1^b

^aP values were calculated by χ² test.

^bP values were calculated by Fisher’s exact test.

The control group received chemotherapy combined with bevacizumab. The experimental group received chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy.

Table 5 Baseline hematological prognostic indicators markers for patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy, mean ± SD

Characteristics	Stats	Normal range
Height (cm)	162.6 ± 8.2	140-190
Weight (kg)	61.0 ± 8.9	40-100
ALLC (10⁹/L)	6.1 ± 2.2	3.5-9.5
ANC (10⁹/L)	5.9 ± 11.1	1.8-6.3
ALC (10⁹/L)	1.6 ± 0.6	1.1-3.2
AMC (10⁹/L)	0.4 ± 0.2	0.1-0.6
PLT (10⁹/L)	253.5 ± 79.7	125-350
AEC (10⁹/L)	0.3 ± 0.5	0.02-0.52
RDW (%)	14.7 ± 3.2	11.6-14.8
FIB (g/L)	3.7 ± 1.5	2-4
Dimer (ng/mL)	879.3 ± 1162.6	0-500
LDH (IU/L)	257.5 ± 150.4	109-245
ALB (g/L)	41.5 ± 4.0	40-55
CEA (ng/mL), n (%)	10 (35.7)	0-5
CEA (ng/mL), n (%)	18 (64.3)	0-5
CA199 (IU/mL), n (%)	19 (67.9)	0-37
CA199 (IU/mL), n (%)	9 (32.1)	0-37

ALLC: Absolute leukocyte count; ANC: Absolute neutrophil count; ALC: Absolute lymphocyte count; AMC: Absolute monocyte count; PLT: Platelet; AEC: Absolute eosinophil count; RDW: Red blood cell distribution width; FIB: Fibrinogen; LDH: Lactate dehydrogenase; ALB: Albumin; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199.

Table 6 Univariate and multivariate Cox analysis of prognostic factors in microsatellite stable metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy, n (%)

Dependent: Survival (PFS/30, status)		All	HR (univariable)	HR (multivariable)
Age	> 60	10 (35.7)	-	-
Age	≤ 60	18 (64.3)	1.47 (0.52-4.15, P = 0.466)	-
Gender	Male	15 (53.6)	-	-
Gender	Female	13 (46.4)	1.34 (0.52-3.41, P = 0.543)	-
Location	Right colon	15 (53.6)	-	-
Location	Left colon and rectum	13 (46.4)	4.02 (1.38-11.70, P = 0.011)	1.34 (0.25-7.36, P = 0.733)
Number of metastatic organs	1	22 (78.6)	-	-
Number of metastatic organs	≥ 2	6 (21.4)	0.90 (0.26-3.14, P = 0.870)	-
Liver metastasis	No	10 (35.7)	-	-
Liver metastasis	Yes	18 (64.3)	0.73 (0.27-1.99, P = 0.540)	-
Lung metastasis	No	21 (75.0)	-	-
Lung metastasis	Yes	7 (25.0)	1.20 (0.42-3.42, P = 0.727)	-
RAS	Unknown	8 (28.6)	-	-
	Wild type	5 (17.9)	1.61 (0.34-7.57, P = 0.544)	-
	Mutation	15 (53.6)	1.52 (0.42-5.52, P = 0.524)	-
CEA	1	10 (35.7)	-	-
CEA	2	18 (64.3)	2.11 (0.74-6.01, P = 0.161)	-
CA199	1	19 (67.9)	-	-
CA199	2	9 (32.1)	3.70 (1.27-10.77, P = 0.016)	2.56 (0.43-15.18, P = 0.301)
NLR	≤ 3.96	23 (82.1)	-	-
NLR	> 3.96	5 (17.9)	4.72 (1.24-17.88, P = 0.023)	1.79 (0.19-17.36, P = 0.614)
LMR	≤ 6.45	25 (89.3)	-	-
LMR	> 6.45	3 (10.7)	2.44 (0.67-8.84, P = 0.174)	-
BMI	≤ 18.73	3 (10.7)	-	-
BMI	> 18.73	25 (89.3)	4.38 (0.56-34.10, P = 0.159)	-
ALI	≤ 205.20	9 (32.1)	-	-
ALI	> 205.20	19 (67.9)	0.37 (0.14-1.00, P = 0.049)	0.33 (0.14-13.15, P = 0.805)
SII	≤ 926.18	21 (75.0)	-	-
SII	> 926.18	7 (25.0)	3.11 (1.10-8.81, P = 0.033)	2.54 (0.32-20.29, P = 0.379)
ALLC	≤ 4.85	8 (28.6)	-	-
ALLC	> 4.85	20 (71.4)	3.51 (1.12-11.04, P = 0.032)	11.52 (0.52-256.63, P = 0.123)
ANC	≤ 3.13	13 (46.4)	-	-
ANC	> 3.13	15 (53.6)	2.56 (0.95-6.89, P = 0.064)	0.51 (0.07-3.53, P = 0.493)
ALC	≤ 1.15	7 (25.0)	-	-
ALC	> 1.15	21 (75.0)	1.87 (0.53-6.60, P = 0.332)	-
AMC	≤ 0.32	7 (25.0)	-	-
AMC	> 0.32	21 (75.0)	3.38 (0.96-11.90, P = 0.058)	1.30 (0.15-11.13, P = 0.814)
AEC	≤ 0.15	16 (57.1)	-	-
AEC	> 0.15	12 (42.9)	2.52 (0.98-6.46, P = 0.055)	0.54 (0.10-3.07, P = 0.488)
RDW	≤ 13	6 (21.4)	-	-
RDW	> 13	22 (78.6)	0.23 (0.07-0.76, P = 0.016)	0.26 (0.04-1.51, P = 0.133)
LDH	≤ 199	13 (46.4)	-	-
LDH	> 199	15 (53.6)	3.44 (1.24-9.54, P =0 .018)	4.11 (1.02-16.55, P = 0.046)

PFS: Progression-free survival; HR: Hazard ratio; CEA: Carcinoembryonic antigen; CA199: Carbohydrate antigen 199; NLR: Neutrophil-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; BMI: Body mass index; ALI: Advanced lung cancer inflammation index; SII: Systemic immune-inflammation index; ALLC: Absolute leukocyte count; ANC: Absolute neutrophil count; ALC: Absolute lymphocyte count; AMC: Absolute monocyte count; AEC: Absolute eosinophil count; RDW: Red blood cell distribution width; LDH: Lactate dehydrogenase.

Table 7 The predictive value of lactate dehydrogenase in microsatellite stable metastatic colorectal cancer patients receiving chemotherapy combined with bevacizumab and anti-programmed death 1 immunotherapy

Time	AUC	95%CI	Cut-off	Sensitivity	Specificity
9 months	0.81	0.63-0.98	154	0.89	0.75
12 months	0.71	0.47-0.95	343	0.84	0.73
15 months	0.79	0.54-1.04	232	0.93	0.71

AUC: Area under the curve; CI: Confidence interval.

Citation: Gao Z, Wang XY, Shen ZG, Liu JH, Wang XY, Wu SK, Jin X. Real-world comparison of chemotherapy plus bevacizumab with or without immunotherapy as first-line therapy in colorectal cancer. World J Gastroenterol 2025; 31(24): 108298
URL: https://www.wjgnet.com/1007-9327/full/v31/i24/108298.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i24.108298